These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. García-Bosch O; Gisbert JP; Cañas-Ventura A; Merino O; Cabriada JL; García-Sánchez V; Gutiérrez A; Nos P; Peñalva M; Hinojosa J; García-Planella E; Muñoz F; Calvet X; Panés J J Crohns Colitis; 2013 Oct; 7(9):717-22. PubMed ID: 23142005 [TBL] [Abstract][Full Text] [Related]
6. [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study]. Rutka M; Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Molnár T Orv Hetil; 2016 May; 157(18):706-11. PubMed ID: 27106726 [TBL] [Abstract][Full Text] [Related]
7. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. Taxonera C; Iglesias E; Muñoz F; Calvo M; Barreiro-de Acosta M; Busquets D; Calvet X; Rodríguez A; Pajares R; Gisbert JP; López-Serrano P; Pérez-Calle JL; Ponferrada Á; De la Coba C; Bermejo F; Chaparro M; Olivares D; Alba C; Fernández-Blanco I Dig Dis Sci; 2017 Feb; 62(2):481-490. PubMed ID: 27995400 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases. Bank S; Andersen PS; Burisch J; Pedersen N; Roug S; Galsgaard J; Turino SY; Brodersen JB; Rashid S; Avlund S; Olesen TB; Green A; Hoffmann HJ; Thomsen MK; Thomsen VØ; Nexø BA; Vogel U; Andersen V Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748864 [TBL] [Abstract][Full Text] [Related]
10. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience. Teisner AS; Ainsworth MA; Brynskov J Scand J Gastroenterol; 2010 Dec; 45(12):1457-63. PubMed ID: 20701434 [TBL] [Abstract][Full Text] [Related]
11. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Gies N; Kroeker KI; Wong K; Fedorak RN Aliment Pharmacol Ther; 2010 Aug; 32(4):522-8. PubMed ID: 20500733 [TBL] [Abstract][Full Text] [Related]
12. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P; J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996 [TBL] [Abstract][Full Text] [Related]
14. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030 [TBL] [Abstract][Full Text] [Related]
15. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study). Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929 [TBL] [Abstract][Full Text] [Related]
16. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease. Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674 [TBL] [Abstract][Full Text] [Related]
18. Similar Short- and Long-term Colectomy Rates with Ciclosporin and Infliximab Treatment in Hospitalised Ulcerative Colitis Patients. Duijvis NW; Ten Hove AS; Ponsioen CI; van den Brink GR; Buskens CJ; Bemelman WA; Te Velde AA; D'Haens GR; Löwenberg M J Crohns Colitis; 2016 Jul; 10(7):821-7. PubMed ID: 26818660 [TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea. Seo H; Chang K; Lee SH; Song EM; Kim GU; Seo M; Lee HS; Hwang SW; Yang DH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH Scand J Gastroenterol; 2017 Aug; 52(8):857-863. PubMed ID: 28502189 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice. Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Rutka M; Molnár T J Crohns Colitis; 2016 Jan; 10(1):26-30. PubMed ID: 26392413 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]